205 related articles for article (PubMed ID: 19238112)
1. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome.
Eguchi T; Nomura Y; Hashiguchi T; Masuda K; Arata M; Hazeki D; Ueno K; Nishi J; Kawano Y; Maruyama I
Pediatr Infect Dis J; 2009 Apr; 28(4):339-41. PubMed ID: 19238112
[TBL] [Abstract][Full Text] [Related]
2. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study.
Gaïni S; Pedersen SS; Koldkjaer OG; Pedersen C; Møller HJ
Crit Care; 2007; 11(2):R32. PubMed ID: 17346334
[TBL] [Abstract][Full Text] [Related]
3. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
Kobayashi T; Inoue Y; Takeuchi K; Okada Y; Tamura K; Tomomasa T; Kobayashi T; Morikawa A
Circulation; 2006 Jun; 113(22):2606-12. PubMed ID: 16735679
[TBL] [Abstract][Full Text] [Related]
4. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[TBL] [Abstract][Full Text] [Related]
5. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease.
Hoshina T; Kusuhara K; Ikeda K; Mizuno Y; Saito M; Hara T
Scand J Rheumatol; 2008; 37(6):445-9. PubMed ID: 18720262
[TBL] [Abstract][Full Text] [Related]
6. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[TBL] [Abstract][Full Text] [Related]
7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
8. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis.
Yasuda T; Ueda T; Takeyama Y; Shinzeki M; Sawa H; Nakajima T; Ajiki T; Fujino Y; Suzuki Y; Kuroda Y
Pancreas; 2006 Nov; 33(4):359-63. PubMed ID: 17079940
[TBL] [Abstract][Full Text] [Related]
9. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
Egami K; Muta H; Ishii M; Suda K; Sugahara Y; Iemura M; Matsuishi T
J Pediatr; 2006 Aug; 149(2):237-40. PubMed ID: 16887442
[TBL] [Abstract][Full Text] [Related]
10. New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis.
Gaïni S; Pedersen SS; Koldkaer OG; Pedersen C; Moestrup SK; Møller HJ
Clin Exp Immunol; 2008 Mar; 151(3):423-31. PubMed ID: 18190604
[TBL] [Abstract][Full Text] [Related]
11. Non-classical Kawasaki disease in a 2 month old infant.
Hartmann I; Weiss K; Bistritzer T; Baram S; Goldman M
Isr Med Assoc J; 2006 Aug; 8(8):581-2. PubMed ID: 16958253
[No Abstract] [Full Text] [Related]
12. Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis.
Tahara M; Baba K; Waki K; Arakaki Y
Acta Paediatr; 2006 Dec; 95(12):1661-4. PubMed ID: 17129979
[TBL] [Abstract][Full Text] [Related]
13. Platelet vascular endothelial growth factor is a useful predictor for prognosis in Kawasaki syndrome.
Ueno K; Nomura Y; Hashiguchi T; Masuda K; Morita Y; Hazeki D; Eguchi T; Maruyama I; Kawano Y
Br J Haematol; 2010 Jan; 148(2):285-92. PubMed ID: 19793253
[TBL] [Abstract][Full Text] [Related]
14. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
15. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
Kubota M; Usami I; Yamakawa M; Tomita Y; Haruta T
J Paediatr Child Health; 2008 Jun; 44(6):359-62. PubMed ID: 18476929
[TBL] [Abstract][Full Text] [Related]
16. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT
J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population.
Fukami A; Adachi H; Yamagishi S; Matsui T; Ueda S; Nakamura K; Enomoto M; Otsuka M; Kumagae S; Nanjo Y; Kumagai E; Esaki E; Murayama K; Hirai Y; Imaizumi T
Metabolism; 2009 Dec; 58(12):1688-93. PubMed ID: 19616266
[TBL] [Abstract][Full Text] [Related]
18. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ; Kim KH; Chun JK; Kim DS
Yonsei Med J; 2008 Oct; 49(5):714-8. PubMed ID: 18972590
[TBL] [Abstract][Full Text] [Related]
19. Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy.
Yamamoto N; Sato K; Hoshina T; Kojiro M; Kusuhara K
Mod Rheumatol; 2015; 25(6):898-902. PubMed ID: 25849851
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
